An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

Part of paid clinical trials in La Jolla, California.

Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Study ID
NCT07197866
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Multiple System Atrophy

Eligibility Criteria

Sex
ALL
Age
30 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TEV-56286 — DRUG
    administered orally

Study Details

The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.

Key Dates

Start date
Sep 30, 2025
Status verified
Jun 2026
Primary completion
May 3, 2029
Completion
May 17, 2029

Study Design

Enrollment
200 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TEV-56286

Primary Outcome Measure

Number of participants experiencing an adverse event [ Time Frame: Baseline to Week 100 ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
Teva Investigational Site 15554La JollaCalifornia92037-
Teva Investigational Site 15544Boca RatonFlorida33486-
Teva Investigational Site 15555TampaFlorida33613-
Teva Investigational Site 15549New YorkNew York10016-
Teva Investigational Site 15551New YorkNew York10032-3726-
Teva Investigational Site 15543SpokaneWashington99202-

Find similar trials in La Jolla, CA

By research site
Teva Investigational· La Jolla, CATeva Investigational· Boca Raton, FLTeva Investigational· Tampa, FLTeva Investigational· New York, NYTeva Investigational· Spokane, WA

Related Studies